Rosuvastatin. Opt for statins with evidence of efficacy on clinical outcome

Prescrire International

Volumn 13, Issue 72, 2004, Pages 132-134

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; CREATINE KINASE; CYCLOSPORIN; CYTOCHROME P450; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; FLUOROBENZENE; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ABDOMINAL PAIN; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CLINICAL STUDY; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MARKETING; DRUG USE; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FAMILIAL HYPERCHOLESTEROLEMIA; FRANCE; HETEROZYGOSITY; HUMAN; HYPERCHOLESTEROLEMIA; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; KIDNEY FAILURE; LONG TERM CARE; MEDICAL PARAMETERS; MORBIDITY; MORTALITY; MYALGIA; NAUSEA; NEPHROTOXICITY; OUTCOMES RESEARCH; PROTEINURIA; RHABDOMYOLYSIS; SIDE EFFECT; CHEMISTRY; COMPARATIVE STUDY; DOUBLE BLIND PROCEDURE; DRUG INTERACTION; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; CLINICAL TRIALS; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; PRAVASTATIN; PYRIMIDINES; SIMVASTATIN; SULFONAMIDES; TREATMENT OUTCOME;

EID: 16544369274     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Prescrire Editorial Staff "Statins: new data in secondary prevention and diabetes" Prescrire Int 2003; 12 (66): 143-148.
2. Prescrire Rédaction "Effets indésirables musculaires des statines" Rev Prescrire 2003; 23 (241): 509-514.
3. Prescrire Rédaction "cérivastatine - Staltor° Cholstat°" Rev Prescrire 1998; 18 (190): 806-808.
4. Prescrire Rédaction "Rhabdomyolyse liée à la cérivastatine" Rev Prescrire 2001; 21 (216): 277.
5. Prescrire Rédaction "Rhabdomyolyse liée à la cérivastatine - suite" Rev Prescrire 2001; 21 (220): 595.
6. Olsson AG "A new statin: a new standard" Am J Manage Care 2001; 7 (5 suppl.): 151-154.
7. Olsson AG et al. "Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia" Am J Cardiol 2001; 88: 504-508.
8. Schneck DW et al. "Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease" Am J Cardiol 2003;91: 33-41.
9. Carswell CI et al. "Rosuvastatin" Drugs 2002; 62 (14): 2075-2085.
10. Blasetto JW et al. "Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups" Am J Cardiol 2003; 91 (suppl.) 3C-10C.
11. Davidson M et al. "Comparison of effects on low-density lipoprotein chlolesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia" Am J Cardiol 2002; 89: 268-275.
12. Olsson AG et al. "Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia" Am Heart J 2002; 144: 1044-1051.
13. Brown WV et al. "Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial" Am Heart J 2002; 144: 1036-1043.
14. Paoletti R et al. "Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesteroleamic patients: a randomized, double-blind study" J Cardiovasc Risk 2001; 8: 383-390.
15. McKenney JM et al. "Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial" Current Med Res Opin 2003; 19 (8): 689-698.
16. Chong PH and Yin BT "Rosuvastatin for the treatment of patients with hypercholesterolemia" Ann Pharmacother 2002; 36 93-101.
17. Food and Drug Administration - Center for Drug Evaluation and Research "Statistical review and Evaluation - Clinical studies - Crestor (rosuvastatin calcium)" 27 March 2002: 80 pages.
18. Food and Drug Administration - Center for Drug Evaluation and Research "Clinical review appendix 4 subsection 6-1 Medwatch forms for cases of special interest" 11 June 2003: 40 pages.
19. Public Citizen "Cases of kidney failure, muscle damage should prompt FDA to ban Crestor" Press release, 4 March 2004. Website http://www.citizen.org consulted on 9 March 2004.